Sugi Predict

Sugi Predict / Compounds / Z-Pro-Prolinal

Z-Pro-Prolinal

Z-Pro-Prolinal

SCHEMBL1380758

O=CC1CCCN1C(=O)C1CCCN1C(=O)OCc1ccccc1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 5/20 0.67
▸ CTRB1 P17538 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.54
▸ TSHR P16473 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ KLK7 P49862 1/20 0.53
▸ KLK5 Q9Y337 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ LMNA P02545 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Z-Pro-Prolinal SCHEMBL1219336 1.00 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
Z-Pro-Prolinal SCHEMBL7272251 1.00 PREP (0.67) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL8639445 0.98 PREP (0.65) PREPCTRB1NPSR1TSHRL3MBTL1
Z-Pro-Prolinal SCHEMBL641528 0.94 PREP (0.65) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL2195118 0.90 PREP (0.56) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL2198909 0.90 PREP (0.56) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL2198876 0.90 PREP (0.56) PREPCTRB1NPSR1TSHRL3MBTL1
Z-Pro-Prolinal SCHEMBL8078128 0.90 PREP (0.61) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL9702694 0.89 PREP (0.62) PREPCTRB1NPSR1TSHRL3MBTL1
SCHEMBL9702688 0.89 PREP (0.62) PREPCTRB1NPSR1TSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1713780-B1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2012-01-18 — — EP claimed
JP-4806628-B2 — — 2011-11-02 — — JP claimed
EP-2338490-A2 Combinations Useful for the Treatment of Neuronal Disorders Probiodrug AG (DE) 2011-06-29 — — EP claimed
US-7897633-B2 Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism PROBIODRUG AG (DE) 2011-03-01 — — US claimed
US-20100159032-A1 COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS PROBIODRUG AG (DE) 2010-06-24 — — US claimed
EP-1620091-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2010-03-31 — — EP claimed
US-7655684-B2 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease PROBIODRUG AG (DE) 2010-02-02 — — US claimed
US-20090018087-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2009-01-15 — — US claimed
US-20080194485-A1 Detection and Use of Prolylcarboxypeptidase YALE UNIVERSITY (US) 2008-08-14 — — US claimed
US-7371871-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2008-05-13 — — US claimed
EP-1680120-A2 COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS Probiodrug AG (DE) 2006-07-19 — — EP claimed
EP-1620091-A2 INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2006-02-01 — — EP claimed
WO-2005115446-A2 DETECTION AND USE OF PROLYLCARBOXYPEPTIDASE YALE UNIVERSITY (US) 2005-12-08 — — WO claimed
US-20050215573-A1 Novel inhibitors of glutaminyl cyclase PROBIODRUG AG 2005-09-29 — — US claimed
WO-2005075436-A2 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2005-08-18 — — WO claimed
US-20050171112-A1 Combinations useful for the treatment of neuronal disorders PROBIODRUG AG 2005-08-04 — — US claimed
US-20050137142-A1 Combinations useful for the treatment of neuronal disorders PROBIODRUG AG 2005-06-23 — — US claimed
WO-2005049027-A2 COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS PROBIODRUG AG (DE) 2005-06-02 — — WO claimed
WO-2004098591-A2 INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES PROBIODRUG AG (DE) 2004-11-18 — — WO claimed
US-20040224875-A1 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2004-11-11 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171112-A1 Combinations useful for the treatment of neuronal disorders MME, DNPEP, DPP4 PREP 9/4885CTRB1 460/4885NPSR1 275/4885
US-20040224875-A1 Inhibitors of glutaminyl cyclase GLS2, GLS, GLUL PREP 210/4885CTRB1 4065/4885NPSR1 291/4885
US-20090018087-A1 Novel Inhibitors of Glutaminyl Cyclase GLS2, GLS, GLUL PREP 228/4885CTRB1 4269/4885NPSR1 204/4885
US-20080194485-A1 Detection and Use of Prolylcarboxypeptidase PREP, ENPEP, CPA4 PREP 1/4885CTRB1 82/4885NPSR1 1975/4885
US-20100159032-A1 COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS MME, DNPEP, DPP4 PREP 9/4885CTRB1 460/4885NPSR1 275/4885
US-20050215573-A1 Novel inhibitors of glutaminyl cyclase GLS2, GLS, GLUL PREP 228/4885CTRB1 4269/4885NPSR1 204/4885
US-20050137142-A1 Combinations useful for the treatment of neuronal disorders MME, DNPEP, DPP4 PREP 7/4885CTRB1 243/4885NPSR1 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.